{"entity":{"id":"nct05118789","kind":"trial","name":"A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)","aka":[],"tldr":"A phase 1/2 trial of Zidesamtinib in advanced solid tumours, run by Nuvalent Inc., now recruiting.","summary":"A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) is a phase 1/2 interventional study registered as NCT05118789 by Nuvalent Inc., with 359 participants planned, started 2022-01-04 and due to reach its primary completion in 2027-12-31. Interventions recorded: Zidesamtinib (NVL-520).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05118789","url":"https://clinicaltrials.gov/study/NCT05118789"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["zidesamtinib"],"companies":["nuvalent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05118789","phase":"1/2","setting":"A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)","sponsor":"Nuvalent Inc.","enrolled":359,"outcomes":[]},"route":"/trials/nct05118789/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"zidesamtinib","kind":"drug","name":"Zidesamtinib","route":"/drugs/zidesamtinib/"}],"company":[{"id":"nuvalent","kind":"company","name":"Nuvalent","route":"/companies/nuvalent/"}]}}